Pharmacyclics, Inc. (PCYC) Posts Wider than Expected Q4 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts PCYC Hot Sheet
Price: $261.25 --0%
Financial Fact:
Total revenues: 205.77M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Total revenues: 205.77M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Pharmacyclics, Inc. (NASDAQ: PCYC) reported Q4 non-GAAP loss of ($0.15), versus the analyst estimate of ($0.14). Revenue for the quarter came in at $1.39 million versus the consensus estimate of $2.67 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- First Hawaiian (FHB) Misses Q3 EPS by 7c
- Gorman-Rupp (GRC) Tops Q3 EPS by 16c, Beats on Revenue
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
